Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Lim

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Neuro-Oncology Advances|September 2, 2024
Is pulsed saturation transfer sufficient for differentiating radiation necrosis from tumor progression in brain metastases?Rachel W Chan, Wilfred W Lam, Hanbo Chen, et al.
Neuro-Oncology|December 8, 2021
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-makingMary Jane Lim-Fat, Gilbert C Youssef, Mehdi Touat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Current Oncology (Toronto, Ont.)|July 26, 2024
Canadian Consensus for Treatment of BRAF <i>V600E</i> Mutated Pediatric and AYA GliomasCraig Erker, Magimairajan Issai Vanan, Valérie Larouche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Neuro-Oncology|June 9, 2026
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directionsKarisa C Schreck, Macarena I de la Fuente, Mary Jane Lim Fat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
Nature Cancer|June 3, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomaJack Y Ghannam, Julian Bryan, Jakob Weiss, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Neuro-Oncology Advances|September 2, 2024
Is pulsed saturation transfer sufficient for differentiating radiation necrosis from tumor progression in brain metastases?Rachel W Chan, Wilfred W Lam, Hanbo Chen, et al.
Neuro-Oncology|December 8, 2021
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-makingMary Jane Lim-Fat, Gilbert C Youssef, Mehdi Touat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed GlioblastomaMary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, et al.
Current Oncology (Toronto, Ont.)|July 26, 2024
Canadian Consensus for Treatment of BRAF <i>V600E</i> Mutated Pediatric and AYA GliomasCraig Erker, Magimairajan Issai Vanan, Valérie Larouche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Neuro-Oncology|June 9, 2026
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directionsKarisa C Schreck, Macarena I de la Fuente, Mary Jane Lim Fat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
Nature Cancer|June 3, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomaJack Y Ghannam, Julian Bryan, Jakob Weiss, et al.
Pageof 12